Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALTO 101

Next Previous
Drug Profile

ALTO 101

Alternative Names: ALTO-101T TDS; ALTO-101; ALTO-101T

Latest Information Update: 09 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alto Neuroscience
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Schizophrenia
  • Discontinued Neurodegenerative disorders; Psychiatric disorders

Most Recent Events

  • 03 Oct 2025 ALTO 101 receives Fast Track designation for Schizophrenia [Transdermal] in USA
  • 20 Jun 2024 Alto Neuroscience completes a phase I trial in Schizophrenia (In volunteers) (Transdermal) before June 2024
  • 11 Jun 2024 Phase-II clinical trials in Schizophrenia (Transdermal) in USA (NCT06502964)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top